AAPG
Ascentage Pharma Group InternationalNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.18B
P/E Ratio
—
EPS
$-2.04
Beta
0.81
52W High
$48.45
52W Low
$19.11
50-Day MA
$24.35
200-Day MA
$31.80
Dividend Yield
—
Profit Margin
-216.50%
Forward P/E
—
PEG Ratio
—
About Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
Fundamentals
| Revenue (TTM) | $574.12M |
| Gross Profit (TTM) | $525.18M |
| EBITDA | $-1.13B |
| Operating Margin | -193.30% |
| Return on Equity | -154.60% |
| Return on Assets | -23.00% |
| Revenue/Share (TTM) | $6.45 |
| Book Value | $2.09 |
| Price-to-Book | 11.52 |
| Price-to-Sales (TTM) | 3.80 |
| EV/Revenue | 25.67 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 117.00% |
| Shares Outstanding | $93.33M |
| Float | $283.95M |
| % Insiders | 0.00% |
| % Institutions | 0.07% |
Historical Volatility
HV 10-Day
82.34%
HV 20-Day
71.59%
HV 30-Day
93.02%
HV 60-Day
74.75%
HV Rank
100.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($47.88 target)
2
Strong Buy5
BuyData last updated: 4/28/2026